Artwork for podcast HemaSphere Podcast
Blinatumomab in De Novo AYA ALL - Dr Matthew Greenwood
Episode 2 • 9th February 2026 • HemaSphere Podcast • HemaSphere Journal
00:00:00 00:46:58

Share Episode

Shownotes

In this episode, host HemaSphere Scientific Editor Dr Charley de Bock speaks with Associate Professor Dr Matthew Greenwood about the SUBLIME (ALL09) trial, which explores replacing consolidation chemotherapy with blinatumomab in adolescents and young adults with B‑cell ALL. They discuss why immunotherapy may outperform traditional cytotoxic approaches, how MRD‑guided treatment is reshaping risk stratification, and what future protocols might look like as genomic and immune‑response data are integrated in real time. Dr. Greenwood also shares upcoming innovations—including menin inhibitors, venetoclax‑based MRD targeting, and adaptive platform designs—along with honest insights into the challenges of running clinical trials across Australia.

Links

Chapters

Video

More from YouTube

More Episodes
2. Blinatumomab in De Novo AYA ALL - Dr Matthew Greenwood
00:46:58
1. Inequalities in sickle cell therapies - Dr Stephen Hibbs, Dr Paul Telfer, Mary-Shaniqua - Patient Advocate
00:55:14
8. Defining Lineage in Ambiguous Leukemia: A Transcriptomic View - Dr. Anikó Sijs-Szabó & Roger Mulet Lázaro, PhD
00:35:42
7. EHA/EBMT Survey on Grading and Management of ICAHT - Dr Kai Rejeski
00:40:58
6. Tackling NUP98 Rearranged AML in Pediatric Oncology - Prof Michel Zwaan, Prof Olaf Heidenreich
00:41:07
5. Part 2 - Metabolism in hematology - Ep 3.4
00:28:52
4. Part 1 - Metabolism in hematology - Ep 3.4
00:29:51
3. Machine learning for AML-MRD - Ep 3.3
00:29:23
2. 2 of 2: Navigating Neutropenia: New Guidelines Explained - Ep 3.2
00:28:05
1. Single‐cell DNA and surface protein - Ep 3.1
00:34:16
8. Two distinct fetal-type signatures characterize JMML - Ep 2.8
00:36:59
7. Revolutionizing Pediatric Cancer Research with PDXs - Ep 2.7
00:35:54
6. High 5hmC predicts worse OS - Ep 2.6
00:25:14
5. Informed consent is almost impossible - Ep 2.5
00:39:11
4. Best of Pediatric Hematology from EHA2024 - Ep 2.4
00:42:23
3. NOTCH1 fusions in T‐LBL - Ep 2.3
00:23:34
2. A transcriptional cofactor‐mediated dependency module - Ep 2.2
00:24:47
1. Unraveling the secrets of thrombopoiesis - Ep 2.1
00:25:20
10. What’s so Great About the P-value? A Statistician’s Point of View - Ep 1.8
00:30:23
9. This Is Going to Hurt: Revisiting the Patient Experience of Bone Marrow Biopsies - Ep 1.7
00:24:15
6. 1 of 2: The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children - Ep 1.6
00:27:28
4. Part 1 - Comprehensive Diagnosis and Management of POEMS Syndrome - Ep 1.4
00:23:23
5. Part 2 - Comprehensive Diagnosis and Management of POEMS Syndrome - Ep 1.5
00:24:32
3. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis - Ep 1.3
00:34:01
2. EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer - Ep 1.2
00:24:32
1. Long COVID-19” of Researchers: What to Do Next? - Ep 1.1
00:20:06